[HTML][HTML] Risk-reducing options for high-grade serous gynecologic malignancy in BRCA1/2
L Clarfield, L Diamond, M Jacobson - Current Oncology, 2022 - mdpi.com
Ovarian cancer (OC) is the leading cause of death among women with gynecologic
malignancy. Breast Cancer Susceptibility Gene 1 (BRCA 1) and Breast Cancer Susceptibility …
malignancy. Breast Cancer Susceptibility Gene 1 (BRCA 1) and Breast Cancer Susceptibility …
Risk‐Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act
R Tschernichovsky, A Goodman - The oncologist, 2017 - academic.oup.com
Objective The objective of this study was to review the role of bilateral salpingo‐
oophorectomy in BRCA mutation (m BRCA) carriers and alternative interventions in risk …
oophorectomy in BRCA mutation (m BRCA) carriers and alternative interventions in risk …
Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices
CH Watson, L Soo, BA Davidson… - International Journal of …, 2020 - ijgc.bmj.com
Objective Limited information exists regarding risk reduction strategies for women with
moderate and low penetrance ovarian cancer susceptibility mutations. We sought to assess …
moderate and low penetrance ovarian cancer susceptibility mutations. We sought to assess …
[引用][C] Quality or quantity in the management of hereditary ovarian cancer risk: Is it really a trade-off?
S Masciari, JE Garber - Journal of clinical oncology, 2005 - ascopubs.org
Women with increased probability of developing ovarian cancer face the dilemma of how
best to manage their risk. Lifetime ovarian cancer risk is increased in women who carry …
best to manage their risk. Lifetime ovarian cancer risk is increased in women who carry …
Pathologic findings at risk-reducing salpingo-oophorectomy among women at increased ovarian cancer risk: Results from GOG-199.
PL Mai, ME Sherman, M Piedmonte, OB Ioffe… - 2012 - ascopubs.org
1519 Background: Although risk-reducing salpingo-oophorectomy (RRSO) is a standard
management option for women with BRCA1/2 mutations, the lack of large, prospective …
management option for women with BRCA1/2 mutations, the lack of large, prospective …
NRG-CC008: A nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer …
WK Huh, SL Pugh, JL Walker, K Pennington, EL Jewell… - 2022 - ascopubs.org
TPS10615 Background: Studies of ovarian cancer screening in the general population have
not demonstrated a reduction in ovarian cancer mortality. High-grade pelvic serous …
not demonstrated a reduction in ovarian cancer mortality. High-grade pelvic serous …
Salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: estimating ovarian cancer risk
MG Harmsen, J IntHout, M Arts-de Jong… - Obstetrics & …, 2016 - journals.lww.com
OBJECTIVE: To estimate BRCA1/2 mutation carriers' cumulative ovarian cancer risks after
risk-reducing salpingectomy at various ages with delayed oophorectomy several years later …
risk-reducing salpingectomy at various ages with delayed oophorectomy several years later …
[HTML][HTML] Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO
BL Manning-Geist, M Flint, KL Roche - Gynecologic Oncology Reports, 2023 - Elsevier
In November 2022, the findings of the Avoiding Late Diagnosis of Ovarian cancer (ALDO)
study were published. Subsequent media coverage suggested that investigators had found …
study were published. Subsequent media coverage suggested that investigators had found …
Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations
I Solsky, J Chen, TR Rebbeck - Gynecologic oncology, 2020 - Elsevier
Objectives Current risk-reducing salpingo-oophorectomy (RRSO) guidelines for individuals
with BRCA1/2 mutations do not account for risk variability due to BRCA1/2 cluster region …
with BRCA1/2 mutations do not account for risk variability due to BRCA1/2 cluster region …
[引用][C] Surgical risk-reduction in carriers of BRCA mutations: Where do we go from here?
ND Kauff, RR Barakat - Gynecologic Oncology, 2004 - gynecologiconcology-online.net
In this issue of Gynecologic Oncology, Rosen et al.[1] describe a systematic review of cohort
studies and case series that have looked at the impact of risk-reducing salpingo …
studies and case series that have looked at the impact of risk-reducing salpingo …